A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Phase 1 Completed 21 enrolled AstraZeneca Parexel · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will estimate the relative bioavailability of AZD5055 film-coated tablet as compared to AZD5055 oral suspension. The study will also assess the absolute bioavailabilty of AZD5055 and the effect of food and an acid reducing agent, rabeprazole, on the PK of AZD5055 film-coated tablets when given with food (fed state) or without food (fasted state).

Timeline

Start: 2022-11-04
Primary completion: 2023-02-09
Completion: 2023-02-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD5055	Unknown	—	Intravenous
Subject	Rabeprazole	Small molecule	20 mg	Oral

Indications

No indication recorded.